Correction: Knockdown of THOC1 reduces the proliferation of hepatocellular carcinoma and increases the sensitivity to cisplatin

Correction: J Exp Clin Cancer Res 39, 135 (2020)

https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s13046-020-01634-7

Following the publication of the original article [1], the author identified errors in the images of Figs. 4G and 6D which were unintentionally caused during the figure assembly process. Specifically:

• Figure 4G: R-loop-Vector.

• Figure 6D: R-loop-shNC and Ki67-shNC.

The corrected figures are provided below:

The corrections do not affect the overall results, discussion, or conclusion of the article.

Incorrect Fig. 4

Fig. 4

THOC1 enhances tumorigenesis in vivo. a Relative tumor volume, (b) images of tumor, and (c) tumor weight of PLC/PRF/5 stably transfected with shNC or shTHOC1 plasmids in BALB/c nu/nu mice (Student’s t test; *P < 0.05). d Relative tumor volume, (e) images of tumor, and (f) tumor weight of THOC1-expressing HepG2 cells in nude mice were compared with those of the control vector-transfected HepG2 cells (Student’s t test; *P < 0.05, **P < 0.01). g THOC1 protein expression in subcutaneous xenografts was determined by immunohistochemistry. R-loop level was estimated by S9.6 staining, and cell proliferative activity was measured by PCNA and Ki67 staining (Student’s t test; ***P < 0.001). Scale bar, 50 μm

Correct Fig. 4

Fig. 4

THOC1 enhances tumorigenesis in vivo. a Relative tumor volume, (b) images of tumor, and (c) tumor weight of PLC/PRF/5 stably transfected with shNC or shTHOC1 plasmids in BALB/c nu/nu mice (Student’s t test; *P < 0.05). d Relative tumor volume, (e) images of tumor, and (f) tumor weight of THOC1-expressing HepG2 cells in nude mice were compared with those of the control vector-transfected HepG2 cells (Student’s t test; *P < 0.05, **P < 0.01). g THOC1 protein expression in subcutaneous xenografts was determined by immunohistochemistry. R-loop level was estimated by S9.6 staining, and cell proliferative activity was measured by PCNA and Ki67 staining (Student’s t test; ***P < 0.001). Scale bar, 50 μm

Incorrect Fig. 6

Fig. 6

Luteolin reduces HCC proliferation by targeting THOC1 in vivo and enhances the anti-tumor effect of cisplatin. a Tumor growth curve, (b) representative images of tumor, and (c) tumor weight of PLC/PRF/5 cells stably transfected with shTHOC1 or shNC in BALB/c nu/nu mice treated with 50 mg/kg luteolin or saline as control, respectively (one-way ANOVA; **P < 0.01, ***P < 0.001). d immunohistochemistry staining indicates the expressions of THOC1, R-loop, and proliferation markers (PCNA and Ki67) in tumors (one-way ANOVA; ***P < 0.001). e Tumor growth curve, (f) representative images of tumor, and (g) tumor weight of PLC/PRF/5-bearing BALB/c nu/nu mice. Luteolin or cisplatin treatment significantly suppressed tumor growth. Furthermore, luteolin can enhance the antitumor effect of cisplatin (one-way ANOVA; *P < 0.05, **P < 0.01, ***P < 0.001)

Correct Fig. 6

Fig. 6

Luteolin reduces HCC proliferation by targeting THOC1 in vivo and enhances the anti-tumor effect of cisplatin. a Tumor growth curve, (b) representative images of tumor, and (c) tumor weight of PLC/PRF/5 cells stably transfected with shTHOC1 or shNC in BALB/c nu/nu mice treated with 50 mg/kg luteolin or saline as control, respectively (one-way ANOVA; **P < 0.01, ***P < 0.001). d immunohistochemistry staining indicates the expressions of THOC1, R-loop, and proliferation markers (PCNA and Ki67) in tumors (one-way ANOVA; ***P < 0.001). e Tumor growth curve, (f) representative images of tumor, and (g) tumor weight of PLC/PRF/5-bearing BALB/c nu/nu mice. Luteolin or cisplatin treatment significantly suppressed tumor growth. Furthermore, luteolin can enhance the antitumor effect of cisplatin (one-way ANOVA; *P < 0.05, **P < 0.01, ***P < 0.001)